Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nico Gagelmann"'
Autor:
Marie Robin, Nicolaus Kröger, Gérard Socié, Markus Ditschkowski, Dietrich W. Beelen, Anita Badbaran, Rabia Shahswar, Ioanna Triviai, Michael Heuser, Swann Bredin, Bruno Cassinat, Felicitas Thol, Rashit Bogdanov, Nico Gagelmann
Publikováno v:
Blood. 133:2233-2242
Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis, and current prognostic scoring systems aim to select patients for transplantation. Here, we aimed to develop a prognostic score to determine prognosis after transplantat
Autor:
Victoria Panagiota, Marie Robin, Christine Wolschke, Michael Heuser, Nicolaus Kroeger, Bart L. Scott, Felicitas Thol, Nico Gagelmann, Dietrich W. Beelen, Markus Ditschkowski, Rachel B. Salit, Anita Badbaran, Bruno Cassinat
Publikováno v:
Blood. 138:314-314
Background Circulating peripheral blasts ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis. Recent findings (Masarova et al. Cancer 2020) suggested more differentiated impact of blasts on outcome. However,
Autor:
Radwan Massoud, Nico Gagelmann, Nicolaus Kröger, Wolschke Christine, Tatjana Zabelina, Evgeny Klyuchnikov, Axel R. Zander, Francis Ayuk, Ulrike Fritsche-Friedland
Publikováno v:
Blood. 138:3897-3897
Introduction: Data on the influence of different ATLG doses on immune reconstitution (IR) and GvHD in MUD allo-SCT is limited. In this study, we compared the impact of ATLG doses (30mg/kg vs 60 mg/kg) on IR and transplant outcomes. Methods: In this r
Autor:
Achilles Anagnostopoulos, Guido Kobbe, Claude-Eric Bulabois, Zahit Bolaman, Stephan Mielke, Michel Delforge, Patrick Hayden, Péter Reményi, Andrew M. McDonald, Nico Gagelmann, Tanja Netelenbos, Anne-Marie Stoppa, Maija Itälä-Remes, Meral Beksac, D. J. Eikema, Hélène Labussière-Wallet, Gwendolyn Van Gorkom, Eric Deconinck, Yafour Nabil, Lorenz Thurner, Linda Koster, Ibrahim Yakoub-Agha, William Arcese, Stefan Schönland, Donald Bunjes
Publikováno v:
Blood. 138:485-485
Patient selection becomes crucial for newly diagnosed multiple myeloma (NDMM), to identify those who may benefit the most from specific treatments. This is particularly important for patients for whom evidence of current treatment options remains ver
Publikováno v:
Blood. 134:3113-3113
Background Cellular immunotherapies represent an enormously promising strategy for relapsed/refractory multiple myeloma (RRMM). Chimeric antigen receptor (CAR) T cells targeting B cell maturation antigen (BCMA) have shown impressive results in early-
Autor:
Linda Koster, Hareth Nahi, Simona Iacobelli, Péter Reményi, Xavier Poiré, Stig Lenhoff, Nico Gagelmann, Samo Zver, Dirk-Jan Eikema, Ibrahim Yakoub-Agha, Xavier Leleu, Nicolaus Kroeger, Alexander M Martin, Hélène Schoemans, Pietro Pioltelli, Mark Ringhoffer, Alessandro Rambaldi, Laurent Garderet, Patrice Chevallier, Stefan Schönland, Claude-Eric Bulabois, Didier Blaise, Denis Caillot, Guido Kobbe, Nicola Mordini, Urpu Salmenniemi, Jakob Passweg
Publikováno v:
Blood. 132:2143-2143
Introduction Current consensus identifies translocations t(4;14), t(14;16), t(14;20), and del(17/17p) as high-risk cytogenetics in newly diagnosed multiple myeloma (NDMM). However, evidence on outcome of specific abnormalities according to types of t
Autor:
Stig Lenhoff, Denis Caillot, Clara Mariette, Ann Hunter, Linda Koster, Simona Iacobelli, John A. Snowden, Xavier Leleu, Pietro Pioltelli, Maurizio Musso, William Arcese, Charles Crawley, Michel Delforge, Laurent Garderet, Nicolaus Kröger, Martin R. Schipperus, Nico Gagelmann, Anne-Marie Stoppa, Miklós Udvardy, Tamas Masszi, Maija Itälä-Remes, Hareth Nahi
Publikováno v:
Blood. 128:2266-2266
Introduction Multiple myeloma (MM) is characterized by a proliferation of plasma cells with a strong dependence on the bone marrow (BM) microenvironment. However, in some MM patients this proliferation escapes the BM resulting in extramedullary disea